Trial Profile
Single-center, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial on Estimating the Effect of Probiotic Strain Lactobacillus Reuteri DSM 17938 on Gut Microbiota Modulation in Infants Born by Caesarean Section
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Dysbiosis; Gastrointestinal disorders
- Focus Therapeutic Use
- Sponsors BioGaia
- 14 Sep 2021 Status changed from not yet recruiting to completed.
- 22 Sep 2018 New trial record